Investors’ intense focus on cancer therapies has been a catalyst for biotech ETFs and that focus is expected to intensify in the near-term. With two major cancer conferences imminent, focused biotech ETFs, such as the BioShares Biotechnology Products Fund (NasdaqGM: BBP) and the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), could be on the receiving end of some positive catalysts. [Bet on new Breed Biotech ETFs]
Year-to-date, five of the 10 top-performing non-leveraged sector ETFs are biotech funds, including BBP, BBC, XBI and FBT.
S&P Capital IQ has overweight ratings on FBT and IBB. The research does not currently rate the other ETFs mentioned here.
iShares Nasdaq Biotechnology ETF